hVIVO plc (AIM: HVO)

Market Cap	149.68M
Revenue (ttm)	67.21M
Net Income (ttm)	17.45M
Shares Out	680.37M
EPS (ttm)	0.03
PE Ratio	8.73
Forward PE	14.29
Dividend	0.00 (0.87%)
Ex-Dividend Date	n/a

Volume	175,059
Open	23.50
Previous Close	22.90
Day's Range	22.50 - 23.50
52-Week Range	17.75 - 32.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 11, 2024

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom. The company is involved in testing of vaccines and antivirals using human challenge clinical trials; and offers laboratory services, including assay development, cell based assays, compound efficacy and VRM, field trial bio-logistics, molecular, and biomarker analysis services. It provides services to big pharma and biotech organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19,...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Yamin Khan
• Employees: 274
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: HVO